The first evidence that cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, could have antipsychotic properties was published in 1982. (1) This study investigated the interaction between THC and CBD in health volunteers. The co-administration of the two cannabinoids induced less anxiety and psychotomimetic symptoms than THC alone. The antipsychotic impact of CBD got further help with the report of a higher frequency of acute psychotic episodes in patients admitted in psychiatric hospital after the use of a variety of cannabis virtually devoid of CBD. (2)
In a study using hair samples of 140 individuals to analyze levels of cannabinoids, Morgan and Curran (2008) showed that those with only THC in their hair exhibited higher levels of hallucinations and delusions than individuals with both THC and CBD, and those with no cannabinoids (3). In a case–control study with 280 people with a first episode of psychosis and 174 controls, Di Forti et al. (2009) showed that patients were significantly more likely to have used high-potency cannabis, containing high THC and low CBD concentrations, compared to controls who preferred resin (hash), usually containing equal amounts of THC and CBD. In addition, psychosis was associated with more frequent and longer use of cannabis (Di Forti et al., 2009). (4) Another study with 410 first episode psychosis patients revealed that the use of high potency cannabis, containing less CBD, also resulted in an earlier age of onset of psychosis (Di Forti et al., 2014). (5)
Altogether, studies that inspected the effect of CBD/THC proportions in cannabis on measures important for psychosis demonstrate that the utilization of cannabis with high CBD content is related with essentially fewer side effects, for example, delusions and hallucinations and also with better subjective capacity and lower risk for creating psychosis.
Schizophrenia is a severe, often lifelong mental disorder that significantly affects how a person thinks, feels and behaves in an adverse manner.
Symptoms (6) may include:
One examination led by Western University in California inferred that CBD might be valuable in treating schizophrenia and related types of psychosis. The examination drove by Justine Renard, a postdoctoral individual in the college's Department of Anatomy and Cell Biology at the Schulich School of Medicine and Dentistry, distinguished the neural pathway where the CBD produces antipsychotic impacts found to reduce manifestations of schizophrenia-related psychosis. “These findings have critical implications not only for understanding how specific phytochemical components of marijuana may differentially impact neuropsychiatric phenomena, but demonstrate a potential mechanism for the therapeutic effects of marijuana derivatives in the treatment of dopamine-related, psychiatric disorders,” the study said. (7) Specialists infused rats with CBD to study its behavioral, substance and neuropathic impacts and found that it reduces dopamine sensitization, a reaction that has been connected to schizophrenia-related psychoses. This clarifies precisely how CBD influences the brain function, something previously unknown. It likewise indicates a novel approach for treating psychoses, something scientists say is enormously required.
Another study, published in the June 2017 issue of Neuropsychopharmacology, suggested that CBD is very effective in managing symptoms associated with schizophrenia. Dr. Katrina Green, a supervisor of the study, stated, “From this review, we found that CBD will not improve learning and memory in healthy brains, but may improve aspects of learning and memory in illnesses associated with cognitive impairment, including Alzheimer’s disease, as well as neurological and neuro-inflammatory disorders. Evidence suggests that CBD is neuroprotective and can reduce cognitive impairment associated with the use of THC, the main psychoactive component of cannabis.” (8)
As you can see, the proof is to a great extent for CBD being a powerful treatment for schizophrenia, among other mental issues. CBD's capacity to connect with different systems in the body, combined with the way that it reduces extra side effects that conventional pharmaceuticals don't, may make it a powerful instrument in future treatment plans.
This article was written by an independent and third-party author specialising in CBD, hemp and cannabis research. Any opinion, advice or recommendation expressed in the article does not reflect the opinion of Formula Swiss AG or any of our employees. We do not make any claims about any of our products and refer to our disclaimer for more information.
Comments will be approved before showing up.